Market Cap (In KRW)
169.37 Billion
Revenue (In KRW)
3.08 Billion
Net Income (In KRW)
-12.76 Billion
Avg. Volume
217.51 Thousand
- Currency
- KRW
- Country
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 10830.0-22150.0
- PE
- -
- EPS
- -
- Beta Value
- 0.073
- ISIN
- KR7174900001
- CUSIP
- -
- CIK
- -
- Shares
- 17425100.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Industry
- CEO
- Kim Kyu-Tae
- Employee Count
- -
- Website
- https://www.abclon.com
- Ipo Date
- 2017-09-18
- Details
- AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.
More Stocks
-
6177
-
1888
-
MITFYMitie Group plc
MITFY
-
RESTILERestile Ceramics Limited
RESTILE
-
KPIGREENKPI Green Energy Limited
KPIGREEN
-
1938
-
HYDHydrix Limited
HYD
-
688737